Clinical Trial Update: Silencing Inflammatory Activity by Injecting Nanocort in Patients at Risk for Atherosclerotic Disease [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating injections of Nanocort to silence inflammatory activity in patients at risk for atherosclerotic disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Inflammation

Drugs mentioned

• Nanocort

Snippet

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Conditions: Atherosclerosis, Inflammation | Phase 1, Phase 2 | Status: UNKNOWN